{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit could not be determined within 95% confidence interval due to low enrollment.The limited sample size is not enough to accurately estimate the upper limit of the confidence interval. A larger sample size would be needed to get a more reliable estimate.","groupId":"OG000","lowerLimit":"7.85","upperLimit":"NA","value":"13.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Duration of MM patients treated with bendamustine, bortezomib and pegylated liposomal doxorubicin. from first date of at least partial response to the time of progression or death due to disease progression as events, with disease progression and death due to disease progression as events and deaths due to causes other than progression as censored. Censoring date will be the last disease evaluation date or date of death due to other causes as appropriate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine:\n\nAt phase II, Bendamustine will be administered at 90mg/m\\^2 by IV over 1 hour at days 1 and 4 of the 28 day treatment cycle.\n\nDoxorubicin:\n\nPegylated liposomal doxorubicin at phase II will be administered at 30 mg/m2 by IV over 1 hour,at day 4 of the 28 day treatment cycle.\n\nBortezomib:\n\nBortezomib at Phase II will be administered at 1.3 mg/m2 by IV bolus or SQ injection on days 1, 4, 8, and 11 of the 28 day cycle.","id":"OG000","title":"Phase II : Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin."}],"paramType":"MEDIAN","populationDescription":"Two subjects never received treatment. Therefore, they were not included in any assessment of objectives.","reportingStatus":"POSTED","timeFrame":"From C1D1 up to a maximum of 52 months","title":"Phase II: Duration of Survival","type":"SECONDARY","unitOfMeasure":"months"}